Statherin vs PACAP-27
Head-to-head comparison of Statherin (Human statherin) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.
| Property | Statherin | PACAP-27 |
|---|---|---|
| Category | Dental & Oral | Diabetes & Metabolic |
| Full Name | Human statherin | Pituitary Adenylate Cyclase-Activating Polypeptide-27 |
| Molecular Weight | 5380 Da | 3158 Da |
| Half-Life | minutes to hours in saliva | minutes |
| Amino Acids | 43 | 27 |
| Typical Dose | 1-50 µM in experimental systems | Research-only: 0.1-1 nmol/kg |
| Route | Topical/Intraoral | Intraperitoneal/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 95 | 220 |
| Research Status | Pre-clinical | Pre-clinical |
Statherin Benefits
- ✓enamel pellicle stabilization
- ✓calcium phosphate homeostasis
- ✓remineralization support
- ✓anti-adhesion
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Statherin Dosing
topical peptide exposure in vitro or ex vivo|salivary-mimetic coating studies|surface-conditioning protocols
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Statherin Side Effects
- ⚠minimal systemic effects expected
- ⚠surface adsorption variability
- ⚠rapid enzymatic breakdown
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Research Overview
Statherin
Statherin has been extensively studied as a key regulator of enamel mineral equilibrium and pellicle biology. It is used in biomimetic dentistry research to model or improve enamel protection and remineralization.
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.